Article
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology - 1 Mar 2020
Belderbos Bodine P S, de With Mirjam, Singh Rajbir K, Agema Bram C, El Bouazzaoui Samira, Oomen-de Hoop Esther, de Wit Ronald, van Schaik Ron H N, Mathijssen Ron H J, Bins Sander
Abstract excerpt
PURPOSE: Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with adverse events which may require dose reductions or discontinuation of treatment. We investigated the potential association of single-nucleotide polymorphisms (SNPs) in genes encoding drug transporters and drug-metabolizing enzymes with cabazitaxel toxicity, overall survival (OS) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
